"Melphalan" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen.
| Descriptor ID |
D008558
|
| MeSH Number(s) |
D02.455.526.728.650.594 D12.125.072.050.685.500
|
| Concept/Terms |
Melphalan- Melphalan
- L-PAM
- Phenylalanine Mustard
- Mustard, Phenylalanine
- 4-(Bis(2-chloroethyl)amino)phenylalanine
|
Below are MeSH descriptors whose meaning is more general than "Melphalan".
Below are MeSH descriptors whose meaning is more specific than "Melphalan".
This graph shows the total number of publications written about "Melphalan" by people in this website by year, and whether "Melphalan" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 0 | 1 | 1 |
| 2004 | 3 | 0 | 3 |
| 2005 | 1 | 2 | 3 |
| 2007 | 1 | 0 | 1 |
| 2008 | 1 | 1 | 2 |
| 2009 | 0 | 3 | 3 |
| 2010 | 0 | 1 | 1 |
| 2011 | 2 | 3 | 5 |
| 2012 | 1 | 0 | 1 |
| 2013 | 1 | 1 | 2 |
| 2014 | 1 | 1 | 2 |
| 2015 | 3 | 3 | 6 |
| 2016 | 0 | 2 | 2 |
| 2017 | 4 | 0 | 4 |
| 2019 | 1 | 1 | 2 |
| 2021 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Melphalan" by people in Profiles.
-
Shields CL, Dockery PW, Yaghy A, Duffner ER, Levin HJ, Taylor OS, Sajjadi Z, Lally SE, Shields JA, Rosenwasser R, Tjoumakaris S, Jabbour P. Intra-arterial chemotherapy for retinoblastoma in 341 consecutive eyes (1,292 infusions): comparative analysis of outcomes based on patient age, race, and sex. J AAPOS. 2021 06; 25(3):150.e1-150.e9.
-
Ravindran K, Dalvin LA, Pulido JS, Brinjikji W. Intra-arterial chemotherapy for retinoblastoma: an updated systematic review and meta-analysis. J Neurointerv Surg. 2019 Dec; 11(12):1266-1272.
-
Camp DA, Lally SE, Shields CL. Heterochromia following intravitreal chemotherapy in two cases. J AAPOS. 2019 08; 23(4):241-243.
-
Shields CL, Sioufi K, Mashayekhi A, Shields JA. Intravitreal Melphalan for Treatment of Primary Vitreoretinal Lymphoma: A New Indication for an Old Drug. JAMA Ophthalmol. 2017 07 01; 135(7):815-818.
-
Mark TM, Guarneri D, Forsberg P, Rossi A, Pearse R, Perry A, Pekle K, Tegnestam L, Greenberg J, Shore T, Gergis U, Mayer S, Van Besien K, Ely S, Jayabalan D, Sherbenou D, Coleman M, Niesvizky R. A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple Myeloma. Biol Blood Marrow Transplant. 2017 Jun; 23(6):930-937.
-
Magan T, Khoo CT, Jabbour PM, Shields CL. INTRAARTERIAL CHEMOTHERAPY FOR RETINOBLASTOMA IN A 2-MONTH-OLD INFANT. Retin Cases Brief Rep. 2017 Winter; 11(1):24-26.
-
Choe HK, Gergis U, Mayer SA, Nagar H, Phillips AA, Shore TB, Smith MJ, van Besien K. The Addition of Low-Dose Total Body Irradiation to Fludarabine and Melphalan Conditioning in Haplocord Transplantation for High-Risk Hematological Malignancies. Transplantation. 2017 Jan; 101(1):e34-e38.
-
Shields CL, Shields JA. Intra-arterial Chemotherapy for Retinoblastoma. JAMA Ophthalmol. 2016 10 01; 134(10):1201.
-
Shields CL, Douglass AM, Beggache M, Say EA, Shields JA. INTRAVITREOUS CHEMOTHERAPY FOR ACTIVE VITREOUS SEEDING FROM RETINOBLASTOMA: Outcomes After 192 Consecutive Injections. The 2015 Howard Naquin Lecture. Retina. 2016 Jun; 36(6):1184-90.
-
Patel K, Parmar S, Shah S, Shore T, Gergis U, Mayer S, van Besien K. Comparison of Subcutaneous versus Intravenous Alemtuzumab for Graft-versus-Host Disease Prophylaxis with Fludarabine/Melphalan-Based Conditioning in Matched Unrelated Donor Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2016 Mar; 22(3):456-61.